Joint Clinical Assessment (JCA): Overview, process and timelines under EU HTA

Joint Clinical Assessment (JCA) is the joint European assessment of the relative clinical effectiveness and safety of certain health technologies. It addresses clinical questions submitted by EU Member States and is coordinated with the EU marketing authorisation procedure. The process comprises seven key stages, from initiation and PICO scoping to dossier submission, assessment and publication of the JCA report.

Regulation (EU) 2021/2282 introduces JCA progressively. Certain new oncology medicines and advanced therapy medicinal products (ATMPs) have been covered since 13 January 2025, with further categories following in 2028 and 2030.

JCA does not replace national HTA, nor does it determine added benefit, pricing or reimbursement. The JCA report provides a common clinical evidence base for consideration in national HTA procedures.

Regulatory reference date: October 2026. Procedural time limits follow the HTACG Procedural Guidance (version 1.0, November 2024). The legal instruments and currently applicable guidance governing an individual assessment remain authoritative.

All guides on the Joint Clinical Assessment at a glance

This guide is the entry point to the JCA: it explains the process, timelines and framework. The following guides go deeper into individual areas.

• Scoping and PICO: How the assessment scope and PICOs come about, and how evidence planning can be aligned with them, is described in the guide on JCA scoping and PICO.

• Dossier: Structure, evidence requirements and submission are explained in the JCA dossier guide.

• Evidence assessment: The methodological requirements for randomised trials, indirect comparisons and non-randomised evidence are summarised in the guide on JCA evidence assessment.

• Scientific advice: Advice before the procedure is described in the guide on Joint Scientific Consultation.

• National level in Germany: What applies nationally after the JCA is covered in the guides on the AMNOG process and the AMNOG dossier.

Current analyses of the first procedures are provided in the insights Joint Clinical Assessment: What the First Four JCA Reports Reveal About Evidence Assessment and Discontinued JCAs: Why Joint Clinical Assessments are discontinued.

The JCA process at a glance

The JCA process is coordinated with the centralised marketing authorisation procedure at the European Medicines Agency (EMA). National HTA bodies undertake the clinical assessment, coordinated through the HTA Coordination Group.

The stages are interdependent. The interval between communication of the final assessment scope and dossier submission is particularly important for evidence planning.

Regulatory framework for Joint Clinical Assessment

Regulation (EU) 2021/2282 establishes a common European framework for assessing relative clinical effectiveness and safety. Member States retain responsibility for their national appraisal, pricing and reimbursement decisions.

Medicines subject to JCA from 2025, 2028 and 2030

The relevant eligibility conditions are set out particularly in Article 7 of Regulation (EU) 2021/2282. An orphan medicine may already fall within JCA before 2028 if it belongs to a category covered since 2025.

Responsibilities of the HTA Coordination Group and JCA participants

An assessor and co-assessor carry out the scientific assessment, while the HTA Coordination Group coordinates joint work at EU level.

Assessors come from different Member States and are selected with regard to relevant therapeutic and methodological expertise. Patients and clinical experts may contribute, particularly to scoping and clinical assessment.

EMA marketing authorisation versus Joint Clinical Assessment

EMA marketing authorisation and JCA address different questions. Marketing authorisation examines quality, safety and efficacy within the proposed indication. JCA examines relative clinical effectiveness and safety against the comparators defined in its assessment scope.

Evidence sufficient for marketing authorisation may therefore not address every JCA comparator. The two procedures are coordinated but lead to distinct outputs.

The seven stages of the JCA process: From EMA submission to the JCA report

The JCA process follows seven interconnected stages coordinated with EU marketing authorisation. The assessment scope, submission deadline and requests during assessment are especially relevant to manufacturers.

Stage 1: Identification and initiation of the JCA

A medicine potentially subject to JCA is identified in connection with the planned EMA marketing authorisation application. The HTD supplies the required information and an assessor and co-assessor are appointed. Formal initiation is linked to submission of the marketing authorisation application.

Operational preparation should begin earlier, during clinical development, when relevant populations, comparators and evidence needs can still inform study and analysis planning.

Stage 2: Development of the assessment scope and PICO scoping

PICO scoping identifies the clinical questions to be addressed in the JCA. The assessor and co-assessor prepare a draft scope, and Member States submit requirements through the PICO survey. PICO stands for population, intervention, comparator and outcomes.

Member States may differ in their relevant populations, standards of care and outcome requirements. Scoping seeks to reflect these different clinical assessment needs within the joint assessment.

Stage 3: Consolidation and finalisation of the JCA assessment scope

PICO consolidation brings Member State requirements into a common assessment scope. It seeks to cover relevant clinical questions efficiently without excluding required questions. The final scope may contain one or several PICOs.

The HTA Secretariat communicates the final scope and requests the JCA dossier. The developer may request an assessment scope explanation meeting, which clarifies the scope rather than reopening PICO negotiations or providing scientific advice on proposed methods.

The separate guide JCA scoping and PICO: Assessment scope, comparators and evidence planning under EU HTA explains consolidation and early preparation in depth.

Stage 4: Preparation and submission of the JCA dossier

The JCA dossier presents clinical evidence addressing the PICOs in the final assessment scope. The standard submission period is 100 days from the first formal request for dossier submission, or generally 60 days in accelerated authorisation procedures. The applicable period begins with the formal request in the individual JCA procedure.

The dossier includes relevant clinical studies, systematic evidence identification, direct and indirect comparisons, and results for relative clinical effectiveness and safety. Extensive searches and evidence synthesis may need to begin before the final scope is available.

The guide JCA dossier: Structure, evidence requirements and submission under EU HTA covers the dossier sections, supporting documents and evidence presentation.

Stage 5: Completeness check of the JCA dossier

After submission, the dossier is checked for completeness. The standard period is 15 working days, or 10 working days in an accelerated procedure. Missing information may trigger a second request. According to the HTACG Procedural Guidance, the revised submission includes a tracked-changes version, a clean version and a cover letter. Generally, 15 days are available to respond, or 10 days in accelerated procedures. Seven days may apply to minor missing information.

Completeness is distinct from scientific validity. This stage checks whether the required material has been provided, not whether every analysis is methodologically convincing. Failure to submit a complete dossier within the applicable process can lead to discontinuation of the JCA.

Stage 6: Scientific assessment of clinical evidence

The assessor and co-assessor examine relative clinical effectiveness and safety for the defined PICOs. They consider direct and indirect comparisons, population and comparator suitability, internal and external validity, statistical precision and risk of bias.

Additional specifications, clarifications, data or analyses may be requested during assessment. Depending on the request, response windows can range from seven to 30 days. New clinical data submitted to the EMA during the process may also be relevant.

The guide JCA evidence assessment: Methodological requirements for RCTs, indirect comparisons and non-randomised evidence covers the underlying methods.

Stage 7: Factual accuracy check and finalisation of the JCA report

Before publication, the developer can identify technical or factual inaccuracies in the revised draft report. The usual period is seven days, with five days applying in certain circumstances, including accelerated procedures.

This is not an opportunity to renegotiate the scientific assessment. Following further review, the JCA Subgroup validates the report and the HTA Coordination Group endorses it. For medicines, endorsement is intended no later than 30 days after the European Commission's marketing authorisation decision.

JCA report: Content, review and publication

The JCA report documents the joint assessment of relative clinical effectiveness and safety, including the principal limitations and uncertainties. It is the central output of the European assessment.

Content of the JCA report and summary report

The report presents evidence and findings against the PICOs, including the studies and analyses considered, relative clinical effects, internal validity, applicability, statistical precision and uncertainty. A summary report sets out the principal findings. Neither document provides an EU-wide national added-benefit determination.

The insight Joint Clinical Assessment: What the first four JCA reports reveal about evidence assessment analyses the first published reports, and Tovorafenib after the JCA shows how a JCA outcome carries over into the German G-BA benefit assessment. Ongoing and completed procedures are tracked in JCA Watch.

Factual accuracy check by the developer

The HTD can identify factual or technical inaccuracies and flag information considered commercially confidential. The short review window requires the relevant scientific and regulatory teams to be available. It is not a second scientific consultation.

Publication of the JCA report

After validation and endorsement, the JCA report and summary report are made available through the applicable European publication process. They provide a common clinical evidence base for national HTA, while national requirements and decisions remain in place.

JCA timelines and procedural deadlines

JCA contains several short deadlines coordinated with the EMA procedure. Dossier submission, completeness checks, follow-up requests and factual accuracy review require advance planning.

These periods have different triggering events. The exact starting point and any exceptions must be checked against the applicable procedural rules.

Coordination of EMA marketing authorisation and JCA timelines

The EMA marketing authorisation application is a key reference point for JCA initiation and coordination. Scoping and dossier preparation overlap with major regulatory milestones. The final assessment scope precedes dossier submission, while scientific assessment is coordinated with the marketing authorisation process.

Dossier submission deadlines and additional requests

The 100-day submission window can be challenging where the final scope includes comparators or populations not fully addressed in the pivotal development programme. Requests after submission also require capacity for rapid analysis and quality assurance.

Joint Clinical Assessment and national HTA procedures

The JCA report provides a common European clinical evidence base but does not replace national HTA. Member States remain responsible for national assessments and decisions.

Use of the JCA report in national HTA

National HTA bodies must give appropriate consideration to the published JCA report. The common assessment is intended to reduce duplication and establish shared information on relative clinical effects. National appraisal can nevertheless address questions specific to a country's healthcare system.

Additional national evidence requirements

National assessments may need additional analyses where the European PICOs do not fully address national populations, comparators or outcomes. New data and country-specific information may also matter. Non-clinical HTA domains, including costs, epidemiology, healthcare context and health economics, remain national responsibilities.

EMA marketing authorisation, JCA and national HTA compared

Germany retains the AMNOG early benefit assessment; in France, the competent bodies of the Haute Autorité de santé (HAS) continue national appraisal.

How the JCA dossier differs from the national AMNOG dossier, and how European evidence is translated into a Delta-Dossier, is explained in the insight Five theses on the Delta-Dossier.

JCA and AMNOG at a glance

The JCA and the AMNOG benefit assessment answer different questions and run side by side.

The JCA dossier does not replace the AMNOG dossier; both submissions can share clinical content. Structure and delimitation are described in the guides on the JCA dossier and the AMNOG dossier, the national procedure in the guide on the AMNOG process.

Preparing for JCA: Priorities for health technology developers

Operational JCA readiness starts before dossier submission. The interface with EMA authorisation, the final assessment scope and short response windows require coordinated work across functions.

Aligning regulatory and JCA planning

JCA planning should follow key EMA milestones, including submission, scoping, dossier preparation and the anticipated authorisation decision. Changes in the regulatory timeline can affect the JCA schedule. Regulatory affairs, clinical development, biostatistics, HEOR and market access need a coordinated plan.

Evidence preparation before the final assessment scope

Potential populations, comparators and outcomes can be anticipated before the scope is finalised. Early review of studies, gaps and feasible analyses can reduce pressure after the formal request. The dedicated PICO scoping guide covers scenario planning in detail.

Coordinating European and national HTA preparation

Developers should identify which European PICOs are likely to be relevant nationally and where additional analyses may be required. In Germany this includes the relationship between JCA PICOs and AMNOG requirements. Early coordination can reduce inconsistencies and duplicated work.

Joint Scientific Consultation as an earlier advice opportunity

Joint Scientific Consultation (JSC) enables developers to seek scientific advice on evidence needs during clinical development. JSC is distinct from JCA and is not one of the seven stages of a particular JCA. Eligibility, procedure and outputs are covered in the separate JSC guide.

Sources and regulatory references

• Regulation (EU) 2021/2282 on health technology assessment.

• Commission Implementing Regulation (EU) 2024/1381 on joint clinical assessments of medicinal products.

• European Commission and HTA Coordination Group: procedural guidance on JCA and assessment scope.

• European Commission and HTA Coordination Group: methodological guidance for clinical evidence assessment.

• European Commission: published Joint Clinical Assessment reports and summary reports.